January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
January 2025 in “Journal of Prescribing Practice”
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
3 citations
,
November 2020 in “Clinical, Cosmetic and Investigational Dermatology” Early diagnosis and combination therapy, especially with finasteride and dutasteride, are key to managing Frontal Fibrosing Alopecia effectively.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
November 2025 in “Acta Dermato Venereologica” Effective immunomodulatory treatments and a personalized approach are crucial for managing severe folliculitis decalvans.
14 citations
,
November 2024 in “Pharmaceuticals” Spanlastic nano-vesicles improve famotidine's effectiveness and absorption.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
October 2025 in “Carbohydrate Polymer Technologies and Applications” TM-β-CD improves finasteride's solubility and delivery, while β-CD offers better long-term release.
22 citations
,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
2 citations
,
January 2012 in “Journal of Clinical & Experimental Dermatology Research” Fexofenadine reduces discomfort but doesn't significantly improve hair regrowth in Alopecia Areata treatment.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
September 2015 in “Photodiagnosis and Photodynamic Therapy” January 2025 in “Biochemical Pharmacology” Peficitinib can turn human fibroblasts into cells that help grow hair.
January 2022 in “Drug Delivery” The aloe ferox gel with finasteride and oregano oil may effectively treat alopecia.
The tablets are easy to make, look good, work well, and are ready for mass production.
64 citations
,
June 2009 in “Journal of The American Academy of Dermatology” Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.
February 2024 in “Current Bioactive Compounds” The new gel formulation effectively delivers Finasteride for hair growth treatment without skin irritation.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
10 citations
,
October 2019 in “Australasian Journal of Dermatology” Secukinumab effectively treated a difficult case of folliculitis decalvans.
42 citations
,
July 2015 in “Drug Development and Industrial Pharmacy” Flutamide, delivered by solid lipid nanoparticles, could potentially treat hair loss.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
July 2012 in “Reactions Weekly” Crushed finasteride tablets can harm pregnant and fertile women.
1 citations
,
January 2020 in “Archives of Medical Research” Formononetin, found in red clover, may treat hair loss with fewer side effects.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.